Last reviewed · How we verify

paracetamol + pregabalin + dexamethasone

Glostrup University Hospital, Copenhagen · FDA-approved active Small molecule

This combination reduces pain through acetaminophen's analgesic action, pregabalin's modulation of calcium channels to reduce neuropathic pain, and dexamethasone's anti-inflammatory effects.

This combination reduces pain through acetaminophen's analgesic action, pregabalin's modulation of calcium channels to reduce neuropathic pain, and dexamethasone's anti-inflammatory effects. Used for Acute and chronic pain management, Neuropathic pain, Postoperative pain with inflammatory component.

At a glance

Generic nameparacetamol + pregabalin + dexamethasone
Also known asAcetaminophen, Pregabalin, Dexamethasone
SponsorGlostrup University Hospital, Copenhagen
Drug classCombination analgesic/neuropathic pain agent
TargetCOX inhibition (paracetamol); voltage-gated calcium channels (pregabalin); glucocorticoid receptor (dexamethasone)
ModalitySmall molecule
Therapeutic areaPain Management, Neurology
PhaseFDA-approved

Mechanism of action

Paracetamol inhibits prostaglandin synthesis in the central nervous system to provide analgesia. Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing the release of excitatory neurotransmitters involved in pain signaling. Dexamethasone, a corticosteroid, suppresses inflammatory mediators and immune responses that contribute to pain and inflammation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: